Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.
Health Professionals
Dr Moser on Treatment Considerations After Progression on Frontline PD-1 Inhibitors in Melanoma
Justin Moser, MD, a medical oncologist at HonorHealth and an associate clinical investigator at HonorHealth Research Institute, discussed therapeutic decision-making for patients with advanced melanoma who progress following initial treatment with checkpoint inhibitor–based combinations, such as nivolumab (Opdivo) plus ipilimumab (Yervoy) or nivolumab plus relatlimab-rmbw (Opdualag).
The State of Melanoma Care: Advances, Access, and the Road Ahead
In case you missed it, this week we had news about abrocitinib’s flexible dosing for atopic dermatitis, plant-derived exosomes in regenerative skin care, psychosocial support in hidradenitis suppurativa care, and more.
ctDNA After Surgery Identified Patients at High Risk for Early Recurrence in Stage III Melanoma Trial
Measurements of circulating tumor DNA (ctDNA) before adjuvant targeted therapy and during follow-up identified patients with stage III melanoma at high risk for early disease recurrence, according to results of an analysis of patients from the COMBI-AD trial published recently in The Lancet Oncology.